health
care
fastestgrow
sector
us
economi
employ
million
person
hcp
face
rang
noninfecti
hazard
job
includ
back
injuri
strain
sprain
latex
allergi
violenc
stress
hcp
also
commonli
expos
infecti
agent
via
sharp
injuri
eg
hepat
c
viru
hcv
hepat
b
viru
hbv
human
immunodefici
viru
hiv
direct
patient
care
eg
respiratori
virus
gastrointestin
pathogen
pertussi
contamin
environ
eg
clostridium
difficil
case
nonfat
occup
injuri
ill
among
hcp
among
highest
industri
sector
risk
method
prevent
occup
acquisit
infect
hcp
review
minim
risk
diseas
acquisit
base
key
recommend
practic
proper
train
hcp
initi
health
care
practic
annual
eg
infect
control
practic
sharp
injuri
prevent
immun
vaccineprevent
diseas
evalu
hcp
expos
communic
diseas
receipt
pep
adher
standard
precaut
provid
patient
care
especi
perform
appropri
hand
hygien
patient
care
rapid
institut
appropri
isol
precaut
patient
known
suspect
communic
diseas
proper
use
person
protect
equip
mask
respir
eye
protect
gown
care
patient
potenti
communic
diseas
prevent
laboratoryacquir
infect
requir
adher
recommend
administr
protocol
eg
eat
drink
smoke
area
microbiolog
patholog
sampl
process
engin
control
eg
contain
hood
person
protect
equip
eg
mask
cultur
mycobacterium
tuberculosi
appropri
immun
definit
hcp
refer
paid
unpaid
person
provid
servic
health
care
set
potenti
exposur
patient
andor
infecti
materi
includ
bodi
substanc
contamin
medic
suppli
equip
contamin
environment
surfac
contamin
air
hcp
may
includ
limit
list
box
gener
hcp
regular
frequent
contact
patient
bodi
fluid
specimen
higher
risk
acquir
transmit
infect
hcp
brief
contact
patient
environ
eg
bed
food
tray
medic
equip
hcp
work
within
confin
health
care
facil
howev
cover
occup
health
servic
oh
receiv
appropri
screen
preexposur
prophylaxi
even
provid
direct
patient
care
frequent
interact
hcp
provid
direct
care
therefor
risk
acquir
transmit
infecti
pathogen
health
care
personnel
whose
care
cover
occup
health
servic
person
directli
involv
patient
care
eg
cleric
dietari
housekeep
laundri
secur
mainten
administr
bill
volunt
laboratori
mortuari
health
care
set
refer
locat
health
care
provid
includ
limit
facil
provid
acut
care
longterm
care
assist
live
rehabilit
home
health
dialysi
ambulatori
surgeri
also
includ
vehicl
transport
patient
eg
ambul
medic
helicopt
plane
occup
health
program
refer
formal
welldesign
organ
plan
provid
ohss
hcp
commonli
ohss
provid
onsit
within
health
care
facil
hcp
perform
patient
care
may
also
provid
offsit
occup
health
program
includ
varieti
activ
design
minim
risk
hcp
acquir
infecti
diseas
evalu
hcp
potenti
exposur
communic
diseas
evalu
hcp
communic
diseas
box
occup
health
program
awar
appropri
guidelin
center
diseas
control
prevent
profession
organ
adher
appropri
state
feder
law
regul
specif
regul
promulg
us
occup
health
safeti
administr
osha
relat
hcp
includ
bloodborn
pathogen
tuberculosisrespiratori
protect
feder
needlestick
safeti
prevent
act
hr
enact
requir
use
safeti
engin
devic
whenev
possibl
reduc
likelihood
sharp
injuri
new
hcp
undergo
new
personnel
orient
part
orient
process
new
hcp
undergo
screen
educ
direct
reduc
risk
acquisit
infect
diseas
health
care
provid
see
box
inform
obtain
enter
electron
databas
gener
recommend
regard
vaccin
hcp
publish
center
diseas
control
prevent
cdc
advisori
committe
immun
practic
acip
american
academi
pediatr
aap
associ
profession
infect
control
epidemiolog
apic
recent
acip
recommend
summar
yearli
alway
consult
recommend
hcp
immun
mump
measl
rubella
varicella
pertussi
influenza
depend
vaccineprevent
diseas
immun
may
assur
sever
differ
measur
tabl
hcp
immun
receiv
appropri
immun
tabl
even
hcp
consid
immun
vaccineprevent
diseas
transmit
droplet
pertussi
invas
meningococc
infect
mump
rubella
airborn
rout
varicella
wear
mask
prior
enter
room
provid
care
patient
one
diseas
immun
effect
prevent
infect
hcp
potenti
exposur
blood
bodi
fluid
immun
hepat
b
influenza
vaccin
offer
hcp
yearli
past
year
editori
commentari
recommend
yearli
influenza
immun
unless
contraind
condit
employ
hcp
februari
nation
vaccin
advisori
committe
issu
statement
provid
recommend
achiev
healthi
peopl
annual
influenza
vaccin
coverag
goal
hcp
facil
implement
recommend
initi
strategi
consist
achiev
healthi
peopl
goal
vaccin
coverag
hcp
effici
time
manner
recommend
strongli
consid
employ
requir
influenza
immun
hcp
provid
vaccin
recommend
adult
human
papillomaviru
herp
zoster
hz
pneumococc
vaccin
refer
local
medic
provid
special
circumst
hcp
laboratori
personnel
research
offer
immun
vaccin
includ
polio
rabi
hepat
vaccinia
smallpox
anthrax
box
addit
hcp
travel
outsid
unit
state
workrel
activ
evalu
provid
cdc
recommend
immun
typhoid
cholera
japanes
enceph
immunocompromis
hcp
requir
special
consider
provis
immun
first
live
attenu
viru
vaccin
eg
measlesmumpsrubella
mmr
vaccin
varicella
vaccin
live
attenu
influenza
vaccin
laiv
may
contraind
second
vaccin
routin
recommend
may
indic
eg
pneumococc
meningococc
haemophilu
influenza
type
b
third
higher
antigen
dose
eg
hepat
b
vaccin
peopl
endstag
renal
diseas
addit
dose
vaccin
eg
rabi
vaccin
immunocompromis
person
postimmun
serolog
evalu
may
indic
eg
antibodi
hepat
b
surfac
antigen
antihb
titer
hepat
b
vaccin
antibodi
respons
rabi
vaccin
immun
immunocompromis
peopl
may
elicit
lower
antibodi
respons
final
personnel
individu
evalu
reassign
consent
employe
depend
job
duti
care
immunocompromis
patient
contraind
receipt
live
attenu
vaccin
although
hcp
receiv
laiv
work
protect
environ
eg
stem
cell
transplant
unit
day
postimmun
pregnant
hcp
also
requir
special
consider
provis
immun
risk
immun
pregnanc
larg
theoret
benefit
immun
among
pregnant
women
usual
outweigh
potenti
risk
advers
reaction
especi
risk
diseas
exposur
high
infect
would
pose
special
risk
mother
fetu
vaccin
unlik
caus
harm
furthermor
newer
inform
continu
confirm
safeti
vaccin
given
inadvert
pregnanc
ideal
women
childbear
age
includ
hcp
immun
measl
mump
rubella
varicella
tetanu
diphtheria
pertussi
meningococcu
polio
hepat
hepat
b
children
adolesc
becom
pregnant
may
occur
howev
especi
import
hcp
screen
immun
vaccineprevent
diseas
nevertheless
live
attenu
vaccin
provid
nonpregn
hcp
defer
pregnant
women
acip
recommend
healthcar
personnel
administ
tetanu
toxoid
reduc
diphtheria
toxoid
acellular
pertussi
tdap
pregnanc
prefer
third
late
second
trimest
week
gestat
administ
pregnanc
tdap
administ
immedi
postpartum
women
pregnant
respiratori
viru
season
receiv
inactiv
influenza
immun
convinc
evid
risk
immun
pregnant
women
inactiv
viru
bacteri
vaccin
toxoid
suscept
pregnant
women
high
risk
specif
infect
receiv
indic
follow
vaccin
hepat
hepat
b
pneumococc
polysaccharid
meningococc
rabi
polioviru
inactiv
see
box
indic
use
immunoglobulin
prepar
pregnant
nonpregn
women
breastfeed
advers
affect
respons
immun
contraind
current
routin
recommend
vaccin
administr
vaccin
hcp
evalu
presenc
condit
list
vaccin
contraind
precaut
condit
present
risk
benefit
vaccin
need
care
weigh
health
care
provid
patient
common
contraind
histori
anaphylact
reaction
previou
dose
vaccin
vaccin
compon
factor
contraind
immun
includ
follow
household
contact
pregnant
woman
breastfeed
reaction
previou
vaccin
consist
mild
moder
local
tender
swell
fever
less
c
mild
acut
ill
without
lowgrad
fever
current
antimicrobi
therapi
except
oral
typhoid
vaccin
convalesc
recent
ill
person
histori
allergi
except
histori
anaphylact
reaction
vaccin
compon
famili
histori
allergi
seriou
advers
reaction
vaccin
seizur
gener
guidelin
pep
avail
cdc
acip
aap
apic
american
public
health
associ
apha
hcp
educ
occup
health
updat
initi
employ
provid
servic
report
infecti
diseas
exposur
gener
hcp
complet
incid
form
sign
supervisor
report
occup
health
clinic
occup
health
evalu
avail
expos
hcp
incid
form
review
occup
health
commun
worker
compens
depart
hcp
seriou
lifethr
injuri
exposur
refer
emerg
depart
specialti
clinic
appropri
patient
visitor
exposur
also
occur
infect
control
depart
notifi
welldefin
protocol
place
detail
step
evalu
hcp
potenti
expos
infecti
agent
box
proper
counsel
expos
hcp
critic
box
appropri
first
aid
provid
includ
proper
care
sharp
injuri
mucos
membran
exposur
eg
copiou
rins
eye
case
splash
eye
proper
evalu
sourc
case
also
conduct
confirm
report
expos
hcp
sourc
patient
communic
diseas
appropri
laboratori
test
obtain
sourc
patient
determin
sourc
patient
transmit
hiv
hbv
hcv
pep
avail
mani
diseas
includ
limit
diphtheria
hepat
b
hiv
influenza
measl
invas
meningococc
infect
pertussi
rabi
syphili
tuberculosi
varicellazost
pep
also
avail
exposur
includ
anim
bite
eg
dog
cat
rodent
primat
human
bite
unfortun
pep
avail
exposur
arbovirus
hepat
c
mump
parvoviru
rubella
middl
east
respiratori
syndromecoronaviru
pep
may
consist
antivir
antibiot
immunoglobulin
prepar
andor
vaccin
see
box
immunoglobulin
prepar
may
indic
part
pep
exposur
hepat
immun
globulin
ig
hepat
b
ig
hbig
measl
ig
rabi
ig
tetanu
tetanu
ig
varicella
varicellazost
ig
vaccinia
vaccinia
ig
modal
may
recommend
preexposur
prophylaxi
recommend
immun
consid
suffici
protect
exposur
follow
diseas
postexposur
antimicrobi
prophylaxi
still
recommend
pertussi
invas
meningococc
infect
diphtheria
discuss
later
occup
blood
bodi
fluid
exposur
bloodborn
pathogen
remain
seriou
public
health
concern
cdc
estim
million
worker
health
care
industri
relat
occup
risk
occup
exposur
bloodborn
pathogen
differ
pathogen
caus
document
occup
infect
exposur
blood
bodi
fluid
hcp
hospit
laboratori
personnel
import
bloodborn
pathogen
hiv
hbv
hcv
key
featur
assess
risk
transmiss
hbv
hcv
hiv
agent
seropreval
gener
popul
environment
surviv
transmiss
via
percutan
mucou
membran
nonintact
skin
exposur
seropreval
virus
gener
popul
hbv
approxim
hcv
approxim
hiv
approxim
hbv
demonstr
surviv
remain
infecti
greater
day
environment
surfac
data
hcv
environment
surviv
vari
articl
report
surviv
hour
day
week
hiv
halflif
report
hour
maximum
sever
day
risk
transmiss
hbv
depend
rout
exposur
whether
expos
person
immun
via
immun
natur
infect
serolog
statu
sourc
patient
rate
clinic
hepatitisserolog
evid
hbv
infect
suscept
expos
hcp
percutan
exposur
report
sourc
hepat
b
surfac
antigen
hbsag
posit
hepat
b
e
antigen
hbeag
posit
rate
transmiss
report
sourc
hbsag
posit
hbeag
neg
risk
transmiss
hcv
percutan
exposur
report
rang
risk
transmiss
hiv
percutan
exposur
report
ci
addit
percutan
transmiss
bloodborn
virus
hbv
hcv
hiv
transmit
via
blood
contamin
fluid
exposur
mucou
membran
nonintact
skin
human
bite
risk
transmiss
rout
quantit
hbv
hcv
risk
transmiss
mucos
rout
hiv
report
ci
risk
transmiss
hiv
via
exposur
nonintact
skin
like
less
box
postexposur
prophylaxi
counsel
expos
health
care
provid
inform
provid
health
care
provid
expos
infecti
agent
complet
quantifi
risk
human
bite
also
quantifi
transmiss
hbv
hcv
hiv
human
bite
howev
report
human
bite
penetr
skin
howev
consid
possibl
exposur
patienttohcp
hcptopati
cdc
estim
approxim
percutan
injuri
occur
annual
among
hcp
unit
state
time
period
although
incid
needlestick
injuri
reduc
advanc
educ
needl
dispos
engin
chang
personnel
protect
institut
hcp
must
continu
assum
respons
lower
risk
sever
method
reduc
exposur
blood
potenti
infecti
bodi
fluid
describ
box
occup
exposur
blood
potenti
infecti
materi
place
hcp
risk
infect
bloodborn
pathogen
osha
defin
blood
mean
human
blood
blood
compon
product
made
human
blood
potenti
infecti
materi
includ
bodi
fluid
semen
vagin
secret
cerebrospin
fluid
synovi
fluid
pericardi
fluid
pleural
fluid
periton
fluid
human
milk
amniot
fluid
saliva
associ
dental
procedur
bodi
fluid
visibl
contamin
blood
bodi
fluid
consid
infecti
situat
difficult
imposs
differenti
bloodi
fluid
unfix
tissu
organ
intact
skin
human
live
dead
also
consid
potenti
infecti
materi
laboratori
personnel
potenti
infecti
materi
includ
hivcontain
cell
tissu
cultur
organ
cultur
hiv
hepat
viruscontain
cultur
medium
solut
well
blood
organ
tissu
experiment
anim
infect
hiv
hbv
hcv
care
hcp
expos
blood
potenti
contamin
fluid
review
expos
hcp
immedi
provid
box
method
reduc
percutan
mucou
membran
nonintact
skin
exposur
blood
potenti
infecti
bodi
fluid
strict
adher
standard
precaut
includ
appropri
hand
hygien
use
person
protect
equip
eg
glove
gown
mask
eye
shield
use
safeti
engin
devic
needl
syring
scalpel
etc
use
doubleglov
surgic
procedur
increas
risk
glove
punctur
use
blunt
surgic
needl
possibl
work
practic
control
reduc
risk
injuri
elimin
cap
needl
use
tray
pass
sharp
devic
immedi
appropri
discard
use
sharp
instrument
punctur
resist
sharp
dispos
unit
precaut
taken
prevent
sharp
injuri
procedur
cleaningdisinfect
instrument
mouthpiec
resuscit
bag
ventil
devic
avail
whenev
need
anticip
health
care
personnel
exud
lesion
weep
dermat
expos
bodi
area
handswrist
faceneck
must
excus
provid
direct
patient
care
work
patient
equip
osha
regul
enhanc
educ
proper
use
safeti
engin
devic
first
aid
expos
mucou
membran
flush
water
wound
skin
site
contact
blood
bodi
fluid
wash
soap
water
antisept
chlorhexidin
shown
reduc
risk
hbv
transmiss
contraind
howev
use
long
inject
wound
recommend
squeez
wound
express
fluid
use
potenti
harm
agent
bleach
follow
exposur
requir
pep
contact
intact
skin
blood
bodi
fluid
skin
breach
sharp
contact
saliva
nondent
urin
vomit
fece
visibl
contamin
blood
sharp
use
injuri
sourc
patient
blood
bodi
fluid
exposur
test
hiv
use
test
combin
antibodi
antigen
test
hbsag
hepat
c
antibodi
test
indic
sourc
patient
medic
histori
eg
malaria
syphili
htvl
sourc
patient
hcv
test
posit
hcv
polymeras
chain
reaction
pcr
obtain
risk
hbv
acquisit
hcp
declin
dramat
year
number
hbv
infect
among
hcp
declin
approxim
estim
infect
acut
hbv
infect
declin
like
due
decreas
exposur
improv
work
practic
control
see
box
hbv
immun
hcp
risk
hbv
transmiss
patienttohcp
provid
remain
howev
estim
million
person
unit
state
live
chronic
hbv
infect
key
method
prevent
health
careassoci
hbv
infect
among
hcp
hbv
immun
prior
begin
direct
patient
care
hcp
potenti
blood
bodi
fluid
exposur
furthermor
hcp
know
immun
respons
vaccin
hcp
immun
train
initi
patient
contact
antihb
quantit
titer
drawn
month
last
dose
vaccin
hcp
greater
equal
miuml
antihb
consid
immun
life
hcp
respond
adequ
reimmun
addit
dose
vaccin
test
immun
month
last
dose
hcp
respond
adequ
miuml
antihb
test
hbsag
nonrespond
dose
vaccin
counsel
return
report
exposur
blood
bodi
fluid
may
prophylax
hbig
tabl
hcp
especi
traine
remot
histori
hepat
b
vaccin
immun
hbv
assess
use
algorithm
recommend
cdc
hcp
expos
hbsagposit
patient
evalu
prophylaxi
per
recommend
cdc
algorithm
see
tabl
hcp
known
respond
vaccin
miuml
antihb
need
prophylaxi
unimmun
hcp
hcp
unknown
respons
manag
per
cdc
algorithm
may
entail
use
hepat
b
vaccin
andor
hbig
pep
provid
soon
possibl
alway
within
day
exposur
hbig
hepat
b
vaccin
administ
simultan
separ
inject
site
number
person
live
hiv
infect
increas
year
unit
state
due
success
antivir
medic
cdc
estim
approxim
million
peopl
unit
state
live
hiv
end
approxim
know
infect
occup
health
updat
complet
vaccin
ye
hbig
administ
intramuscularli
soon
possibl
exposur
indic
effect
hbig
administ
greater
day
percutan
mucos
nonintact
skin
exposur
unknown
hbig
dosag
mlkg
b
perform
month
last
dose
hepb
vaccin
seri
month
administr
hbig
avoid
detect
passiv
administ
antihb
use
quantit
method
allow
detect
protect
concentr
antihb
miuml
c
respond
defin
person
antihb
miuml
dose
hepb
vaccin
nonrespond
defin
person
antihb
less
miuml
dose
hepb
vaccin
e
hcp
antihb
less
miuml
unvaccin
incomplet
vaccin
sustain
exposur
sourc
patient
hbsagposit
unknown
hbsag
statu
undergo
baselin
test
hbv
infect
soon
possibl
exposur
followup
test
approxim
month
later
initi
baselin
test
consist
total
antihbc
test
approxim
month
consist
hbsag
total
antihbc
unit
state
confirm
possibl
case
occup
acquir
hiv
infect
report
cdc
sinc
confirm
case
laboratori
technician
sustain
needl
punctur
work
live
hiv
cultur
report
manag
hcp
expos
blood
bodi
fluid
hivinfect
person
well
describ
literatur
osha
requir
us
health
care
facil
provid
postexposur
manag
hiv
exposur
consist
recent
us
public
health
servic
guidelin
guidelin
delin
situat
expert
consult
hiv
pep
recommend
well
recommend
followup
hcp
expos
known
suspect
hivposit
sourc
prefer
hiv
pep
regimen
truvada
tenofovir
disoproxil
fumar
tdf
viread
mg
plu
emtricitabineftc
emtriv
mg
tablet
oral
daili
plu
raltegravirr
isentress
mg
oral
twice
daili
tabl
author
retrovirologist
prefer
raltegravir
dolutegravir
dolutegravir
drug
interact
substanti
expens
follow
antiretrovir
agent
use
pep
expert
consult
abacavirabc
ziagen
efavirenzefv
sustiva
fuzeon
fosamprenavirfosapv
lexiva
maravirocmvc
selzentri
saquinavirsqv
inviras
zerit
follow
agent
gener
recommend
pep
didanosin
ddi
videx
ec
nelfinavirnfv
viracept
tipranavirtpv
aptivu
neverapin
nvp
viramun
contraind
pep
neisseria
meningitidi
gramneg
diplococcu
caus
agent
invas
meningococc
diseas
least
serogroup
base
capsular
type
five
serogroup
b
c
w
caus
diseas
worldwid
serogroup
b
c
caus
ill
unit
state
incid
invas
meningococc
diseas
vari
time
age
locat
recent
year
incid
invas
diseas
declin
unit
state
base
tabl
altern
regimen
hiv
postexposur
prophylaxi
occup
health
updat
report
case
cdc
estim
case
death
unit
state
n
meningitidi
transmit
persontoperson
via
respiratori
throat
secret
saliva
spit
close
eg
cough
kiss
lengthi
contact
eg
live
household
carriag
frequenc
n
meningitidi
children
young
adult
approxim
children
among
young
adult
approxim
outbreak
often
occur
commun
school
colleg
prison
close
popul
hcp
acquir
invas
meningococc
infect
result
provid
direct
care
eg
assist
endotrach
intub
airway
suction
infect
patient
estim
clinic
microbiologist
attack
rate
greater
time
high
background
rate
invas
meningococc
diseas
reason
cdcacip
recommend
clinic
research
microbiologist
might
routin
expos
isol
n
meningitidi
receiv
quadrival
meningococc
vaccin
meningococc
serogroup
b
vaccin
menb
fatal
mening
microbiologist
due
n
meningitidi
serotyp
b
recent
report
hcp
receiv
booster
dose
menacwi
everi
year
remain
increas
risk
chemoprophylaxi
household
member
index
case
invas
meningococc
diseas
recommend
chemoprophylaxi
expos
hcp
advis
person
intens
unprotect
contact
eg
without
wear
mask
infect
patient
eg
via
mouthtomouth
resuscit
endotrach
intub
endotrach
tube
manag
chemoprophylaxi
hcp
recommend
even
hcp
vaccin
either
conjug
polysaccharid
vaccin
rate
secondari
diseas
close
contact
highest
immedi
onset
diseas
index
patient
antimicrobi
chemoprophylaxi
administ
soon
possibl
ideal
less
hour
identif
index
patient
convers
chemoprophylaxi
administ
greater
day
exposur
index
patient
probabl
limit
valu
oropharyng
nasopharyng
cultur
help
determin
need
chemoprophylaxi
might
delay
institut
prevent
measur
unnecessarili
strong
evid
sever
antibiot
ie
rifampin
ciprofloxacin
ceftriaxon
moder
evid
antibiot
ie
azithromycin
cefixim
highli
effect
erad
meningococc
carriag
prefer
drug
expos
hcp
rifampin
mg
oral
everi
hour
day
ciprofloxacin
mg
oral
dose
prefer
agent
pregnant
women
ceftriaxon
mg
intramuscularli
dose
dilut
lidocain
decreas
pain
inject
site
although
sporad
resist
rifampin
ciprofloxacin
report
worldwid
meningococc
resist
chemoprophylaxi
antibiot
remain
rare
unit
state
recent
reaffirm
recent
populationbas
surveil
antimicrobi
resist
n
mening
strain
unit
state
strain
test
suscept
ceftriaxon
azithromycin
strain
suscept
ciprofloxacin
rifampin
prior
introduct
varicella
vaccin
varicella
common
diseas
averag
million
peopl
got
chickenpox
hospit
rang
die
year
sinc
introduct
varicella
vaccin
dramat
decreas
number
case
varicella
hospit
death
varicella
may
acquir
exposur
varicella
zoster
howev
exposur
health
care
set
continu
occur
multipl
nosocomi
outbreak
varicellazost
viru
vzv
report
nosocomi
transmiss
attribut
delay
diagnosi
report
varicella
hz
failur
implement
control
measur
promptli
hospit
health
care
set
airborn
transmiss
vzv
patient
either
varicella
hz
result
varicella
hcp
patient
direct
contact
index
case
patient
although
suscept
patient
health
care
set
risk
sever
varicella
diseas
complic
certain
patient
without
evid
immun
increas
risk
pregnant
women
prematur
infant
born
suscept
mother
infant
born
less
week
gestat
weigh
less
equal
g
regardless
matern
immun
statu
immunocompromis
person
age
includ
person
undergo
immunosuppress
therapi
malign
diseas
immunodefici
guidelin
postexposur
manag
hcp
expos
varicella
zoster
publish
cdc
aap
apha
exposur
vzv
defin
close
contact
infecti
person
close
indoor
contact
eg
room
facetofac
contact
expert
differ
regard
durat
contact
suggest
minut
other
hour
agre
includ
transitori
contact
pep
vaccin
varicellazost
ig
depend
immun
statu
expos
hcp
hcp
receiv
dose
vaccin
expos
vzv
varicella
dissemin
hz
uncov
lesion
local
hz
monitor
daili
day
exposur
fever
skin
lesion
system
symptom
suggest
varicella
hcp
monitor
directli
occup
health
program
infectioncontrol
practition
instruct
report
fever
headach
constitut
symptom
atyp
skin
lesion
immedi
hcp
exclud
work
facil
immedi
symptom
occur
hcp
receiv
dose
vaccin
expos
vzv
receiv
second
dose
within
day
exposur
rash
provid
week
elaps
first
dose
vaccin
manag
similar
vaccin
recipi
receiv
second
dose
receiv
second
dose
greater
day
exposur
exclud
work
day
exposur
see
work
restrict
discuss
later
hcp
risk
sever
diseas
varicella
vaccin
contraind
eg
pregnant
immunocompromis
hcp
without
evid
immun
varicellazost
ig
exposur
recommend
varicellazost
ig
product
current
use
unit
state
varizig
cangen
corpor
winnipeg
canada
varizig
indic
administ
soon
possibl
vzv
exposur
ideal
within
hour
greatest
effect
alway
within
day
varizig
suppli
vial
administ
intramuscularli
recommend
dose
kg
bodi
weight
maximum
iu
vial
varizig
indic
avail
greater
day
elaps
sinc
exposur
pep
provid
oral
acyclovir
mgkg
per
dose
administ
time
per
day
maximum
daili
dose
mg
oral
valacyclovir
mgkg
per
dose
administ
time
per
day
maximum
daili
dose
mg
begin
day
postexposur
continu
day
unit
state
highest
record
annual
incid
pertussi
occur
greater
case
report
introduct
diphtheria
tetanu
wholecel
pertussi
vaccin
incid
dramat
declin
recent
year
howev
resurg
pertussi
possibl
occup
health
updat
explan
increas
diseas
includ
genet
chang
bordetella
pertussi
make
vaccin
less
effect
wane
immun
among
children
adolesc
adult
vaccin
childhood
especi
receiv
acellular
pertussi
vaccin
lessen
effect
acellular
pertussi
vaccin
compar
wholecel
vaccin
greater
awar
pertussi
henc
diagnost
test
gener
avail
better
laboratori
test
univers
north
carolina
hospit
pertussi
common
sourc
infecti
diseas
exposur
evalu
david
weber
unpublish
data
multipl
nosocomi
outbreak
pertussi
report
includ
outbreak
infect
hcp
sourc
nosocomi
outbreak
occur
sever
reason
failur
immun
hcp
tdap
failur
recogn
appropri
isol
infect
patient
failur
provid
antibiot
prophylaxi
expos
staff
failur
furlough
symptomat
staff
seropreval
studi
hcp
receiv
pertussi
vaccin
sinc
childhood
reveal
evid
recent
infect
prevent
pertussi
transmiss
health
care
set
involv
diagnosi
earli
treatment
clinic
case
droplet
isol
infecti
patient
exclus
work
hcp
infecti
pep
guidelin
postexposur
manag
hcp
expos
pertussi
publish
cdc
aap
apha
data
need
pep
tdapvaccin
hcp
inconclus
tdap
might
preclud
need
pep
postexposur
antimicrobi
prophylaxi
recommend
hcp
unprotect
exposur
pertussi
like
expos
patient
risk
sever
pertussi
eg
hospit
neonat
pregnant
women
hcp
either
receiv
postexposur
antimicrobi
prophylaxi
monitor
daili
day
pertussi
exposur
treat
onset
sign
symptom
pertussi
b
pertussi
highli
suscept
vitro
erythromycin
newer
macrolid
azithromycin
clarithromycin
also
suscept
trimethoprimsulfamethoxazol
azithromycin
demonstr
effect
prophylaxi
treatment
pertussi
prefer
agent
compar
erythromycin
requir
short
period
pep
therapi
vs
day
reduc
dose
frequenc
vs
time
per
day
less
like
result
gastrointestin
distress
trimethoprimsulfamethoxazol
recommend
altern
treatment
chemoprophylaxi
individu
intoler
macrolid
although
efficaci
chemoprophylact
agent
evalu
tetanu
uncommon
diseas
unit
state
averag
report
case
per
year
nearli
case
tetanu
among
peopl
never
receiv
tetanu
vaccin
adult
stay
current
booster
shot
hcp
greater
risk
tetanu
gener
popul
like
adult
may
acquir
tetanu
insuffici
immun
punctur
wound
contamin
open
wound
burn
crush
injuri
hcp
injuri
could
lead
tetanu
evalu
provid
appropri
pep
base
natur
wound
clean
minor
wound
vs
higher
risk
wound
histori
receipt
tetanu
toxoid
per
recommend
cdc
aap
tetanu
toxoid
diphtheria
toxoid
td
booster
indic
tdap
substitut
hcp
alreadi
receiv
tdap
although
diphtheria
widespread
diseas
unit
state
prior
use
vaccin
rare
diseas
case
report
unit
state
although
diseas
continu
caus
ill
global
casefat
rate
still
hcp
greater
risk
diphtheria
gener
popul
hcp
expos
nasopharyng
secret
patient
known
suspect
diphtheria
follow
postexposur
measur
taken
regardless
immun
statu
surveil
day
evid
diseas
cultur
corynebacterium
diphtheria
antimicrobi
prophylaxi
erythromycin
g
oral
day
singl
inject
penicillin
g
benzathin
million
u
intramuscularli
asymptomat
expos
hcp
also
receiv
booster
dose
td
receiv
booster
dose
diphtheria
toxoidcontain
vaccin
within
year
tdap
prefer
hcp
receiv
dose
tdap
previous
expos
hcp
receiv
equin
diphtheria
antitoxin
evid
antitoxin
provid
addit
benefit
contact
receiv
antimicrobi
prophylaxi
incid
measl
decreas
dramat
sinc
widespread
use
mmr
vaccin
sinc
measl
declar
elimin
unit
state
annual
number
case
rang
low
high
measl
case
unit
state
occur
result
import
peopl
infect
countri
transmiss
may
occur
import
nosocomi
measl
well
document
literatur
may
aid
propag
commun
outbreak
investig
individu
outbreak
report
case
acquir
medic
set
measl
repres
import
health
hazard
hcp
follow
highli
infecti
transmiss
via
airborn
rout
person
becom
infecti
day
onset
characterist
rash
transmiss
outpati
set
occur
even
though
index
case
left
wait
examin
room
minut
earlier
greater
opportun
exposur
hcp
higher
risk
gener
popul
becom
infect
measl
measl
exposur
occur
health
care
facil
nonprotect
hcp
evalu
immedi
presumpt
evid
measl
immun
hcp
without
evid
immun
offer
first
dose
mmr
vaccin
exclud
work
day
exposur
avail
data
suggest
live
viru
measl
vaccin
administ
within
hour
measl
exposur
prevent
modifi
diseas
hcp
without
evid
immun
vaccin
exposur
remov
patient
contact
exclud
facil
day
first
exposur
day
last
exposur
even
receiv
postexposur
intramuscular
ig
mlkg
maxim
dose
volum
ml
document
vaccin
dose
may
remain
work
receiv
second
dose
immunoglobulin
pep
especi
recommend
serosuscept
pregnant
women
immunocompromis
person
intraven
mgkg
ig
administ
expos
person
observ
continu
sign
symptom
measl
day
exposur
ig
might
prolong
incub
period
occasion
outbreak
hepat
viru
hav
report
hospit
risk
factor
hav
transmiss
personnel
includ
activ
increas
occup
health
updat
risk
fecalor
contamin
includ
care
person
unrecogn
hepat
infect
share
food
beverag
cigarett
patient
famili
staff
nail
bite
handl
bile
without
proper
precaut
wash
hand
wear
glove
provid
care
infect
patient
routin
immun
hcp
hepat
vaccin
howev
recommend
seropreval
studi
demonstr
hcp
increas
risk
hav
infect
occup
exposur
mainten
worker
may
expos
sewag
also
increas
risk
acquisit
hepat
need
vaccin
hepat
vaccin
may
use
pep
control
nosocomi
outbreak
person
year
age
case
monoval
hepat
vaccin
use
administ
within
day
exposur
person
year
old
older
ig
mlkg
intramuscularli
use
although
hepat
vaccin
use
ig
avail
efficaci
hepat
vaccin
ig
pep
administ
week
exposur
establish
hcp
may
occasion
suffer
human
bite
especi
care
psychiatr
patient
human
bite
semicircular
oval
area
erythema
bruis
usual
visibl
skin
may
may
intact
wound
care
human
bite
similar
anim
bite
bite
area
manag
follow
clean
wound
antisept
trim
superfici
devit
tissu
remov
foreign
bodi
gross
wound
contamin
assess
injuri
tendon
damag
vascular
damag
penetr
bone
joint
human
bite
left
open
heal
secondari
intent
wound
may
lead
poor
cosmet
result
eg
facial
bite
howev
clinician
may
choos
close
wound
human
bite
frequent
develop
infect
gener
hcp
human
bite
receiv
antimicrobi
prophylaxi
first
dose
provid
soon
possibl
injuri
initi
parenter
dose
antibiot
often
provid
rapidli
obtain
effect
tissu
level
follow
day
oral
antibiot
recommend
specif
antimicrobi
therapi
publish
hcp
suffer
bite
assess
whether
tetanu
prophylaxi
provid
discuss
previous
human
bite
may
lead
patienttohcp
hcptopati
transmiss
bloodborn
pathogen
hiv
hbv
hcv
thu
hcp
expos
person
well
potenti
sourc
transmiss
henc
blood
work
order
sourc
patient
obtain
hcp
rabi
primarili
diseas
anim
epidemiolog
human
rabi
reflect
distribut
diseas
anim
degre
contact
anim
rabi
commonli
acquir
via
bite
scratch
rabid
anim
contact
nonintact
skin
infect
saliva
saliva
nerv
tissu
highli
infecti
gener
contact
bodi
fluid
constitut
exposur
uncommon
rout
infect
includ
contamin
mucou
membran
corneal
transplant
exposur
aerosol
spelunk
laboratori
activ
iatrogen
infect
improperli
inactiv
vaccin
humantohuman
transmiss
rare
report
human
rabi
case
unit
state
rare
case
report
annual
rabi
prophylaxi
may
occasion
need
provid
hcp
work
outofdoor
eg
mainten
worker
personnel
care
ground
suffer
bite
wild
anim
could
potenti
transmit
rabi
fox
raccoon
forth
bat
exposur
concern
rabi
transmiss
frequent
among
hcp
care
human
patient
rabi
especi
fluid
upper
lower
respiratori
tract
human
frequent
test
posit
rabi
viru
one
review
articl
report
approxim
hcp
provid
direct
care
patient
rabi
provid
pep
cdc
recommend
patient
possibl
known
rabi
care
use
standard
precaut
given
hcp
concern
rare
possibl
risk
rabi
transmiss
howev
author
believ
hcp
use
ppe
prevent
contact
patient
saliva
respiratori
secret
ie
gown
glove
face
shield
mask
eye
protect
hcp
mucou
membran
percutan
skin
exposur
potenti
rabid
anim
human
receiv
postexposur
rabi
vaccin
rabi
ig
recommend
cdc
ectoparasit
exposur
hcp
ectoparasit
eg
scabi
pediculosi
like
common
expos
personnel
evalu
sign
symptom
infest
provid
appropri
therapi
confirm
suspect
scabi
prophylact
treatment
provid
personnel
howev
skintoskin
contact
patient
person
ectoparasit
eg
scabi
syphili
hcp
risk
acquir
syphili
via
unprotect
contact
syphilit
skin
lesion
chancr
primari
stage
rash
sore
secondari
stage
also
acquir
via
contact
secret
children
congenit
syphili
prior
standard
practic
use
glove
hcp
examin
patient
skin
lesion
report
extragenit
syphilit
lesion
hcp
therefor
hcp
unprotect
contact
patient
earli
congenit
syphili
identif
diseas
first
hour
therapi
examin
clinic
presenc
lesion
week
contact
serolog
test
perform
repeat
month
contact
sooner
symptom
occur
hcp
unprotect
contact
skin
lesion
patient
primari
secondari
state
diseas
similarli
manag
degre
exposur
consid
substanti
immedi
treatment
consid
current
cdc
sexual
transmit
diseas
treatment
guidelin
use
guid
postexposur
therapi
discuss
previous
hcp
immun
annual
influenza
cdc
howev
provid
detail
recommend
pep
hcp
expos
influenza
well
use
antivir
outbreak
situat
unvaccin
hcp
occup
exposur
use
adequ
person
protect
equip
time
exposur
potenti
candid
chemoprophylaxi
decis
whether
administ
antivir
chemoprophylaxi
take
account
expos
person
risk
influenza
complic
type
durat
contact
recommend
local
public
health
author
clinic
judgment
chemoprophylaxi
antivir
medic
substitut
influenza
vaccin
influenza
vaccin
avail
hcp
receiv
pep
inform
chemoprophylaxi
lower
elimin
risk
influenza
suscept
influenza
return
antivir
medic
stop
influenza
vaccin
recommend
avail
either
oseltamivir
zanamivir
recommend
antivir
chemoprophylaxi
influenza
influenza
occup
health
updat
tabl
recommend
work
restrict
health
care
personnel
colonizedexpos
infect
select
infecti
agent
influenza
b
influenza
viru
infect
emphasi
earli
treatment
altern
chemoprophylaxi
manag
hcp
suspect
exposur
influenza
viru
postexposur
chemoprophylaxi
typic
administ
total
day
recent
known
exposur
close
contact
known
influenza
chemoprophylaxi
also
use
control
measur
outbreak
health
care
facil
especi
hous
patient
higher
risk
influenza
complic
addit
antivir
medic
outbreakcontrol
measur
includ
institut
droplet
contact
precaut
establish
cohort
patient
confirm
suspect
influenza
reoffer
influenza
vaccin
avail
unvaccin
staff
patient
restrict
staff
movement
ward
build
restrict
contact
ill
staff
visitor
patient
chemoprophylaxi
consid
employe
regardless
influenza
vaccin
statu
indic
exist
outbreak
caus
strain
influenza
viru
well
match
vaccin
indic
might
includ
multipl
document
breakthrough
influenza
viru
infect
among
vaccin
person
otherwis
would
expect
respond
vaccin
studi
indic
low
vaccin
effect
circul
surround
commun
suspect
index
case
strain
contain
vaccin
specif
antivir
dose
recommend
drug
dose
rout
durat
avail
cdc
hcp
expos
communic
diseas
suscept
consid
work
restrict
furlough
tabl
similarli
hcp
ill
communic
diseas
suscept
consid
work
restrict
furlough
see
tabl
importantli
infecti
hcp
sourc
patient
infect
index
case
outbreak
hcptopati
transmiss
well
document
hiv
hbv
hcv
commonli
report
hbv
reason
infect
hcp
perform
invas
procedur
evalu
special
panel
need
educ
addit
engin
control
andor
work
restrict
per
current
guidelin
societi
healthcar
epidemiolog
america
cdc
differ
guidelin
describ
